open access

Vol 11, Supp. K (2015)
Case report
Published online: 2016-04-24
Get Citation

Gefitynib in first line treatment of patient with adenocarcinoma of the lung with EGFR exon 18 mutation

Bogdan Żurawski

open access

Vol 11, Supp. K (2015)
CASE REPORTS
Published online: 2016-04-24

Abstract

Non-small-cell lung cancer is one of the major health issues in Poland. EGRF tyrosine kinase inhibitors may be used to treat patients with advanced adenocarcinoma of the lung and remaining in good performance status, with appropriate renal and liver function, without severe comorbidities, and with mutations in the EGRF gene. Until now, the treatment with gefinitib has been applied for the patients with mutations in exon 19 and 21 of the EGRF gene. Efficacy of TKI in the case of the patients with rare activating mutation in exon 18 is not well investigated. This report describes the treatment of 67-year old woman with diagnosed NSCLC with activating mutation in exon 18 who received gefinitib which resulted in 13 months progression-free survival. The treatment was well-tolerated by the patient.

Abstract

Non-small-cell lung cancer is one of the major health issues in Poland. EGRF tyrosine kinase inhibitors may be used to treat patients with advanced adenocarcinoma of the lung and remaining in good performance status, with appropriate renal and liver function, without severe comorbidities, and with mutations in the EGRF gene. Until now, the treatment with gefinitib has been applied for the patients with mutations in exon 19 and 21 of the EGRF gene. Efficacy of TKI in the case of the patients with rare activating mutation in exon 18 is not well investigated. This report describes the treatment of 67-year old woman with diagnosed NSCLC with activating mutation in exon 18 who received gefinitib which resulted in 13 months progression-free survival. The treatment was well-tolerated by the patient.

Get Citation

Keywords

non-small-cell lung cancer, gefitinib, tyrosine kinase inhibitor, mutation in exon 18 of the EGRF gene, rare mutations in EGFR gene

About this article
Title

Gefitynib in first line treatment of patient with adenocarcinoma of the lung with EGFR exon 18 mutation

Journal

Oncology in Clinical Practice

Issue

Vol 11, Supp. K (2015)

Article type

Case report

Published online

2016-04-24

Keywords

non-small-cell lung cancer
gefitinib
tyrosine kinase inhibitor
mutation in exon 18 of the EGRF gene
rare mutations in EGFR gene

Authors

Bogdan Żurawski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl